Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Pharmacokinetics of Oral CellCept (Mycophenolate Mofetil) in Pediatric Liver Transplant Recipients on Concomitant Treatment With Cyclosporine and Corticosteroids

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female participant must be between 3 months and 12 years of age~* Participant is a recipient of a first liver allograft from cadaveric or living donors~* Participant is a single-organ recipient (liver only)~* Female participants of childbearing potential must have a negative serum or urine pregnancy test with a sensitivity of at least 50 milli International Units per milliliter (mIU/mL) within one week prior to PK sampling~* Female participants of childbearing potential must use two reliable forms of contraception simultaneously unless abstinence is the chosen method~* Effective contraception must be used before beginning of PK sampling~* Participants must be able to receive oral medication~* Participants must be at least 6 months post-transplant and had started on MMF in the early post-transplant period (within 2 weeks of transplant)~* Participants must be receiving stable doses of MMF per center practice for at least 7 days prior to PK sampling~* In addition, participants must be receiving stable doses of cyclosporine and corticosteroids, according to center practice~* Participants' parent/guardian are capable of understanding the purposes and risks of the study and must sign an informed consent for the study~Exclusion Criteria:~* Pregnant or nursing adolescents~* Participants who had undergone dialysis within two weeks before PK sampling~* Participants with active systemic infections~* Participants with absolute neutrophil counts (ANC) of less than 1300 per microliter (µL), or platelets counts less than 50 000/µL or hemoglobin at a concentration below a set lower limit (according to center practice, but not less than 8 grams per deciliter) at the time of study entry~* Participants with active peptic ulcer disease~* Participants with severe diarrhea (more than 5 watery stools per day) or other gastrointestinal disorders which might interfere with their ability to absorb oral medication~* History of positive human immunodeficiency virus (HIV) test

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Mycophenolate Mofetil+Corticosteroids+Cyclosporine (Type: EXPERIMENTAL): Part 1: Participants will receive mycophenolate mofetil. Part 2: Participants will receive mycophenolate mofetil along with cyclosporine and corticosteroids.

Based on this trial design, predict the completion outcome and termination type (if applicable).